Telix Pharmaceuticals Limited (OTCMKTS:TLPPF – Get Free Report) traded up 2.3% during mid-day trading on Tuesday . The company traded as high as $9.50 and last traded at $9.41. 2,611 shares were traded during trading, a decline of 27% from the average session volume of 3,555 shares. The stock had previously closed at $9.20.
Telix Pharmaceuticals Trading Up 2.3%
The business’s fifty day moving average price is $9.91 and its 200-day moving average price is $8.59.
Telix Pharmaceuticals Company Profile
Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.
Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.
See Also
- Five stocks we like better than Telix Pharmaceuticals
- The Bank of Mom and Dad Is Booming—3 Stocks to Watch
- Corning Is Paving AI’s Future With Glass
- Why’s Amazon Suddenly Lagging the S&P 500, and Is It a Warning?
- Crypto Winter Is Here: 3 Stocks To Put On Ice This Summer
Receive News & Ratings for Telix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
